Delivery Order SPE2DB22D3301-SPE2DB25FY2PL

Award Date 4/2/25
Potential Completion Date 4/3/25
Potential Value $35K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $11,601.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract is a firm fixed-price delivery order, with an ultimate completion date of July 29, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award, valued at $9,601.35, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $27,760.73, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a Firm Fixed Price Delivery Order with a completion date of July 18, 2024. It is not associated with a set-aside designation, indicating open competition....
This federal contract award, valued at $18,474.64, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. This is a firm fixed-price delivery order contract with a completion date of July 1, 2024. The contract does not have a set-aside designation, indicating open competition....
This federal contract award, valued at $58,590.06, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. This is a firm-fixed-price delivery order contract with an ultimate completion date of October 18, 2023. The contract is not designated with a set-aside requirement, indicating open...
This federal contract award, valued at $10,445.58, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of October 29, 2024. The award is not associated with a set-aside program, indicating open...
This federal contract award, valued at $12,737.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 MG tablets, a medication used to treat overactive bladder. The award has an ultimate completion date of October 25, 2024 and is structured as a firm fixed-price delivery order. This contract does not have a set-aside designation, indicating...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 MG Tablet 90s, a medication for overactive bladder. The contract has a ceiling value of $4,554.41 and runs through March 27, 2025. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen also holds a...
This federal contract award, valued at $7,382.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a firm fixed-price delivery order with an ultimate completion date of April 23, 2025. It is not designated as a set-aside contract, indicating open competition....
This federal contract award, valued at $13,725.74, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract is a Firm Fixed Price Delivery Order that runs through November 2024. It does not have a set-aside designation, indicating open competition. AmerisourceBergen holds...
  • SPE2DB22D3301
    Indefinite Delivery Contract
  • SPE2DB22D3301-SPE2DB25FY2PL
    Delivery Order

This federal contract award, valued at $34,870.99, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used in the treatment of overactive bladder. The contract is a firm-fixed price delivery order with an ultimate completion date of April 3, 2025. The award did not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 7/2/25, 10:29 PM